The DOI matches its Crossref record.
Increased CSF F 2 -isoprostane concentration in probable AD
Abstract
OBJECTIVE: To quantify F2-isoprostane levels in CSF obtained from the lumbar cistern of patients with AD, ALS, and controls. BACKGROUND: Studies of human postmortem tissue and experimental models have suggested a role for oxidative damage in the pathogenesis of several neurodegenerative diseases, especially AD and ALS. F2-isoprostanes are exclusive products of free-radical-mediated peroxidation of arachidonic acid that have been widely used as quantitative biomarkers of lipid peroxidation in vivo in humans. Recently, we showed that F2-isoprostane concentrations are significantly elevated in CSF obtained postmortem from the lateral ventricles of patients with definite AD compared with controls. METHODS: F2-isoprostanes were quantified by gas chromatography/negative ion chemical ionization mass spectrometry. RESULTS: CSF F2-isoprostanes were increased significantly in patients with probable AD, but not in ALS patients, compared with controls. CONCLUSIONS: Increased CSF F2-isoprostanes are not an inevitable consequence of neurodegeneration and suggest that increased brain oxidative damage may occur early in the course of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy
Forman, H. J., & Zhang, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00233-1 · Cited by 2,900
Halliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502
Reactive oxygen species, cell signaling, and cell injury
Hensley, K., Robinson, K. A., Gabbita, S. P., Salsman, S., & Floyd, R. A. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00252-5 · Cited by 1,019
Measurement of F2-isoprostanes as an index of oxidative stress in vivo
Roberts, L. J., & Morrow, J. D. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00264-6 · Cited by 996
Self-citationOxidative stress: The core pathogenesis and mechanism of Alzheimer’s disease
Bai, R., Guo, J., Ye, X.-Y., Xie, Y., & Xie, T. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101619 · Cited by 813
Isoprostanes: markers and mediators of oxidative stress
Montuschi, P., Barnes, P. J., & Roberts, L. J. (2004) · The FASEB Journal · doi:10.1096/fj.04-2330rev · Cited by 747
Self-citationConquer, J. A., Tierney, M. C., Zecevic, J., Bettger, W. J., & Fisher, R. H. (2000) · Lipids · doi:10.1007/s11745-000-0646-3 · Cited by 524
Montine, T. J., Neely, M. D., Quinn, J. F., Beal, M. F., Markesbery, W. R., Roberts, L. J., & Morrow, J. D. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00807-9 · Cited by 449
Self-citationLipid peroxidation cannot be used as a universal criterion of oxidative stress
Dotan, Y. (2004) · Progress in Lipid Research · doi:10.1016/j.plipres.2003.10.001 · Cited by 434
Williams, T. I., Lynn, B. C., Markesbery, W. R., & Lovell, M. A. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.06.004 · Cited by 392
Lipid peroxidation and neurodegenerative disease
Reed, T. T. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.027 · Cited by 379
Oxidative injury in diseases of the central nervous system: focus on alzheimer’s disease
Praticò, D., & Delanty, N. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00547-7 · Cited by 378
Galasko, D. R., Peskind, E., Clark, C. M., Quinn, J. F., Ringman, J. M., Jicha, G. A., Cotman, C., Cottrell, B., Montine, T. J., Thomas, R. G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.85 · Cited by 377
Self-citationThe isoprostanes—25 years later
Milne, G. L., Dai, Q., & Roberts, L. J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.10.007 · Cited by 335
Self-citationIncreased oxidative damage to DNA in ALS patients
Bogdanov, M., Brown, R. H., Matson, W., Smart, R., Hayden, D., O’Donnell, H., Flint Beal, M., & Cudkowicz, M. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00349-x · Cited by 334
Self-citationClinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis
D’Amico, E., Factor-Litvak, P., Santella, R. M., & Mitsumoto, H. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.029 · Cited by 321
Oxidative Stress in Alzheimer’s Disease: Why Did Antioxidant Therapy Fail?
Persson, T., Popescu, B. O., & Cedazo-Minguez, A. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/427318 · Cited by 312
F2-Isoprostanes as markers of oxidative stress in vivo: An overview
Milne, G. L., Musiek, E. S., & Morrow, J. D. (2005) · Biomarkers · doi:10.1080/13547500500216546 · Cited by 312
Self-citationThe Role of Oxidative Stress in Alzheimer Disease
Markesbery, W. R. (1999) · Archives of Neurology · doi:10.1001/archneur.56.12.1449 · Cited by 306
Giasson, B. I., Ischiropoulos, H., Lee, V. M.-Y., & Trojanowski, J. Q. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00804-3 · Cited by 279
Elevated CSF prostaglandin E 2 levels in patients with probable AD
Montine, T. J., Sidell, K. R., Crews, B. C., Markesbery, W. R., Marnett, L. J., Roberts, L. J., & Morrow, J. D. (1999) · Neurology · doi:10.1212/wnl.53.7.1495 · Cited by 277
Self-citationLipid peroxidation is an early event in the brain in amnestic mild cognitive impairment
Markesbery, W. R., Kryscio, R. J., Lovell, M. A., & Morrow, J. D. (2005) · Annals of Neurology · doi:10.1002/ana.20629 · Cited by 273
Self-citationThe role of lipid peroxidation in neurological disorders
Shichiri, M. (2014) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.14-10 · Cited by 269
F 2 -Isoprostanes in Human Health and Diseases: From Molecular Mechanisms to Clinical Implications
Basu, S. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1956 · Cited by 268
Biomarkers of Alzheimer disease in plasma
Irizarry, M. C. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.226 · Cited by 268
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment
de Leon, M. J., DeSanti, S., Zinkowski, R., Mehta, P. D., Pratico, D., Segal, S., Rusinek, H., Li, J., Tsui, W., Saint Louis, L. A., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.07.003 · Cited by 253
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Oxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
Conte, V., Uryu, K., Fujimoto, S., Yao, Y., Rokach, J., Longhi, L., Trojanowski, J. Q., Lee, V. M., McIntosh, T. K., & Praticò, D. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02560.x · Cited by 164
Circulating Biomarkers of Cognitive Decline and Dementia
Solfrizzi, V., D'Introno, A., Colacicco, A. M., Capurso, C., Todarello, O., Pellicani, V., Capurso, S. A., Pietrarossa, G., Santamato, V., Capurso, A., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.015 · Cited by 120
Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods
Fonteh, A. N., Harrington, R. J., Huhmer, A. F., Biringer, R. G., Riggins, J. N., & Harrington, M. G. (2006) · Disease Markers · doi:10.1155/2006/202938 · Cited by 113
Haddad, M., Hervé, V., Ben Khedher, M. R., Rabanel, J.-M., & Ramassamy, C. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8129 · Cited by 68
Alzheimer's disease biomarkers: correspondence between human studies and animal models
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27
Alzheimer’s disease: from early pathogenesis to novel therapeutic approaches
Prajapati, S. K., Pathak, A., & Samaiya, P. K. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01389-6 · Cited by 21
Phytochemicals in Alzheimer disease, the development of clinical trials
Quinn, J., Kaye, J., Montine, T., & Stackman, R. (2004) · Pharmaceutical Biology · doi:10.3109/138802090893531 · Cited by 8
“F2 isoprostane levels in postmortem brain are correlated with brain atrophy (Montine et al., 1999b).”
BackgroundSelf-citation
Metadata
- Authors
- Montine, T. J., Beal, M. F., Cudkowicz, M. E., O’Donnell, H., Margolin, R. A., McFarland, L., Bachrach, A. F., Zackert, W. E., Roberts, L. J., & Morrow, J. D.
- Venue
- Neurology
- Published
- 1999-02
- Volume
- 52
- Issue
- 3
- Pages
- 562-562
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2015847846
- Cited by
- 251
- References
- 0
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.